Rapid Readouts: Extended Follow-up From the Phase 3 ARAMIS trial
June 30th 2021Neal Shore, MD, presents data on the tolerability of and responses to darolutamide (DARO) as seen in the extended follow-up of the phase 3 ARAMIS trial of DARO treatment in men with high-risk, nonmetastatic, castration-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Rapid Readouts: Treatment Preference Results From the Phase 2 ODENZA Trial
June 30th 2021Neal Shore, MD, presents data on treatment preferences from the phase 2 ODENZA trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Advanced Prostate Cancer: Remaining Challenges
Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.
Read More
Risk Factors in Advanced Prostate Cancer
Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.
Read More
Advanced Prostate Cancer: New Findings From ASCO GU 2021
Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.
Read More
The First Oral GNRH Receptor Antagonist for Advanced Prostate Cancer
Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.
Read More